L03AA03 • molgramostim • Antineoplastic and immunomodulating agents | Immunostimulants | Colony stimulating factors
Molgramostimum is a medication used for the treatment of certain rare lung conditions, such as autoimmune pulmonary alveolar proteinosis. It is a recombinant form of granulocyte-macrophage colony-stimulating factor (GM-CSF), which helps improve lung function by stimulating the clearance of accumulated proteins in the alveoli.
The medication is administered via inhalation under the supervision of a specialist. It is effective in reducing symptoms and improving the quality of life for patients with this rare condition.
Side effects may include coughing, difficulty breathing, fever, or fatigue. In rare cases, severe allergic reactions may occur. It is important to follow your doctor's instructions and monitor your response to treatment.
Consult your doctor to discuss the benefits and risks of treatment with Molgramostimum. Regular monitoring is essential to ensure the therapy's effectiveness.
Substance: molgramostim
Date of last drug list: 01-07-2013
Commercial code: W12060001
Concentration: 150mcg
Pharmaceutical form: lyophilisate for solution for injection+solvent
Quantity: 1
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).